The Conference will return in November 2021, Register Your Interest Here
7:30 am Conference Opens & Networking
Better Understanding of Biomarkers & Biological Mechanisms
8:00 am Lessons in Patient-Focused Drug Development
8:30 am Biomarkers & Precision Medicine in AntiFibrotic Drug Development
9:00 am Non-Invasive Tests (NITs) of Fibrosis for Disease Staging, Prognosis, and Monitoring in Patients With Nash Fibrosis and Other Fibrotic Diseases
9:30 am Link of Disease-specific, Organ-specific Disease Initiation & Tissue Inflammatory & Fibrotic Responses in Different Fibrotic Diseases
Revealing Fibrotic Biomarkers & Endpoints in the Context of Ongoing Clinical Trials
10:00 am Morning Break & Networking
10:30 am Biomarker Lessons From Clinical Trials in Pulmonary Fibrosis
11:00 am Identifying & Refining Fibrosis Biomarkers to Better Inform Trial Design & Create Effective End Points
Hearing About Antifibrotic Drug Development From a Business Angle: What You Need to Know
11:30 am Panel Discussion: Business Development Perspectives on the Fibrosis Space
12:00 pm Lunch & Networking
Analyzing the Potential of the Next Generation of Therapies for Fibrosis & Antifibrotic Therapies Beyond Fibrotic Disease
1:00 pm What can Fibrosis Learn From the Oncology Space & How Can we Apply Learnings from Fibrosis to Oncology?
1:30 pm CAR-T Therapies for Targeting Fibrosis
2:00 pm Lnc’ing Genomic Dark Matter to Next-Generation Antifibrotic Therapies
2:30 pm RNA based therapeutics for the treatment of fibrotic diseases
Lessons Learned from Rarer Fibrotic Indicators
3:00 pm Afternoon Break & Networking
3:30 pm Cardiac Fibrosis: What Makes it Tick?
4:00 pm Bone Marrow Fibrosis, Pathogenesis, Prognosis & Targeted Strategies
4:30 pm Chair’s Closing Remarks
Additional Bonus Content, Pre-Recorded & On-Demand
Addressing Pre-Clinical Drug Development Challenges in Skin & Lung fibrosis
• Chemically - induced model of fibrosis, their advantages and drawbacks
• Lost in translation: the need to incorporate clinically-relevant end points and therapeutic strategies
• Clinically relevant models of skin and lung fibrosis
Manipulating the Fibrosis Molecule – Linking Fibrosis & Cancer
• Discovering how fibrosis and cancer are linked in order to target the appropriate cellular signalling pathways
• Outlining how to use these pathways for antifibrotic and anti-cancer therapy
• Manipulating the fibrosis molecule for anti-fibrotic drug development: What does the future look like?
Harry Karmouty
Assistant Professor
The University of Texas Health Science Center
Anie Philip
Professor
McGill University